- Dr. Cirle Warren Initiates Pre-Clinical Study for Clostridium Difficile
WESTLAKE VILLAGE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator-based compounds. This preclinical study by Dr. Warren, supported by a National Institutes of Health (NIH) grant, will evaluate these compounds for the treatment of Clostridium difficile (C. difficile) infection, a bacterium that can cause life-threatening inflammation of the colon.
“Earlier research by Dr. Warren demonstrated the potential of our novel compounds to inhibit the inflammatory response from the release of C. difficile toxin. We are excited that Dr. Warren is advancing this research in human neutrophils and intestinal tissues,” said Dr. Ronald Shazer, M.D., Chief Medical Officer of Inspyr Therapeutics. “We look forward to learning more about the potential utility of our adenosine receptor modulators in the management of this aggressive infection and expect to have results in 2018.”
“Half a million patients annually are infected with the Clostridium difficile bacterium, presenting a significant healthcare problem we need to address,” said Cirle A. Warren, M.D., Associate Professor of Medicine, Division of Infectious Disease and International Health, at the University of Virginia School of Medicine.
About Clostridium Difficile
Clostridium difficile (C. difficile) is a bacterium that causes inflammation of the colon and is the most common cause of infectious antibiotic-induced diarrhea. Approximately 500,000 patients annually are infected with C. difficile, according to 2015 estimates from the U.S. Centers for Disease Control and Prevention. A substantial cause of infectious disease death, C. difficile causes an estimated 15,000 deaths annually in the United States.
About Inspyr Therapeutics
Inspyr Therapeutics, Inc. is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation and plasma concentration analysis, assay development, and toxicology. For additional information on Inspyr Therapeutics, visit www.inspyrtx.com.
Inspyr’s Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of Inspyr’s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of Inspyr’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in Inspyr’s periodic reports filed with the Securities and Exchange Commission.
Inspyr Therapeutics Contact:
Lisa Cali
lcali@inspyrtx.com
408-239-7503
